MrMed Logo
Deliver to

Chennai, 600017

Available Brands

Did you find this information helpful?

Author Details
mrmed authentic

Want to know more?
Read Our Editorial Policy

Quick Summary

IXEKIZUMAB

IXEKIZUMAB

Molecule Overview

Ixekizumab is a lab-made antibody that helps calm an overactive immune response involved in certain inflammatory skin and joint conditions. It belongs to a class of medicines called IL-17A inhibitors, used to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It is a prescription-only, self-injectable medicine.

Medical Classification

  • Therapeutic Class: Targeted immunomodulator for inflammatory skin and joint conditions.

  • Pharmacological Class: Interleukin-17A (IL-17A) antagonist.

  • Drug Family: Humanized IgG4 monoclonal antibodies.

  • ATC Classification: L04AC13 (Ixekizumab).

Conditions Treated

  • Approved: Moderate-to-severe plaque psoriasis in adults and children 6 years and older who are candidates for systemic therapy or phototherapy; active psoriatic arthritis in adults; active ankylosing spondylitis in adults; and active non-radiographic axial spondyloarthritis with objective signs of inflammation in adults.

  • Commonly used for: Patients with moderate-to-severe plaque psoriasis affecting quality of life, and patients with inflammatory joint and spine conditions not adequately controlled by other treatments.

  • Off-label use (only under medical guidance): Being studied in other IL-17-driven inflammatory conditions in clinical trials; use outside approved indications is a specialist decision.

Available Strengths & Dosage Forms

●       Injection (prefilled syringe or autoinjector pen, subcutaneous): 80 mg/mL.

How the Molecule Works

Ixekizumab binds to and blocks a protein called interleukin-17A (IL-17A), a key inflammatory messenger that drives the excessive skin cell turnover seen in psoriasis and the joint/spine inflammation seen in psoriatic arthritis and ankylosing spondylitis. By neutralising IL-17A, ixekizumab helps reduce inflammation, skin plaques, and joint symptoms.

Dosage & Administration

  • Standard dose (plaque psoriasis): 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.

  • Condition-wise dose (psoriatic arthritis, ankylosing spondylitis): 160 mg at Week 0, followed by 80 mg every 4 weeks; for non-radiographic axial spondyloarthritis, there is no separate starting dose — treatment is simply 80 mg every 4 weeks.

  • Route: Subcutaneous injection, self-administered after training, typically in the thigh, abdomen, or upper arm.

  • Missed dose: Take as soon as remembered, then resume the regular dosing schedule; don't double up.

  • Overdose: May increase the risk of known side effects such as infection; requires medical attention.

Side Effects

  • Common: Injection-site reactions, upper respiratory tract infections, nausea, and mild to moderate infections (including oral candidiasis and tinea infections).

  • Serious: Increased risk of serious infections, low white blood cell counts (neutropenia), and rare cases of inflammatory bowel disease (new-onset or worsening Crohn's disease or ulcerative colitis).

  • Emergency symptoms: Signs of serious infection (fever, chills, persistent cough), new or worsening abdominal pain with diarrhoea, or signs of a severe allergic reaction (swelling of the face/throat, difficulty breathing).

  • Recovery advice: Testing for tuberculosis and hepatitis before starting, along with prompt reporting of any new infection symptoms, helps manage the infection risk associated with this type of immune-targeted therapy.

Warnings & Precautions

  • Pregnancy: Limited human data; used only if clearly needed, under medical guidance.

  • Breastfeeding: Ixekizumab has been detected in breast milk in animal studies; the benefits of breastfeeding should be weighed against the clinical need for treatment, with the treating doctor.

  • Liver disease: No formal studies conducted on hepatic impairment; used with routine monitoring.

  • Kidney disease: No formal studies conducted on renal impairment; used with routine monitoring.

  • Elderly: No significant differences in safety or efficacy observed between older and younger patients in trials, though used with routine monitoring.

  • Children: Approved for moderate-to-severe plaque psoriasis in children 6 years and older; not established for other indications in children.

Drug Interactions

●       Live vaccines: should be avoided during treatment; patients should be brought up to date on vaccinations before starting.

●       Other biologic immunosuppressants: combining with other biologic therapies is generally avoided due to increased infection risk, unless specifically directed by a specialist.

●       Methotrexate and other conventional DMARDs: can be used alongside ixekizumab in psoriatic arthritis and other joint conditions, as clearance of ixekizumab is not significantly affected by these medicines.

●       CYP450 substrate drugs: IL-17 inhibition can normalise CYP450 enzyme activity that may have been suppressed by chronic inflammation, potentially affecting levels of certain narrow-therapeutic-index drugs metabolised by these enzymes.

Monitoring Requirements

●       Tuberculosis screening before starting treatment.

●       Monitoring for signs of infection throughout treatment.

●       Assessment for new or worsening gastrointestinal symptoms suggestive of inflammatory bowel disease.

●       Periodic clinical review of skin/joint symptom response to guide ongoing treatment decisions.

Alternative Molecules

Secukinumab (another IL-17A inhibitor), Adalimumab, Etanercept (TNF blockers, different mechanism), Guselkumab, Risankizumab (IL-23 inhibitors, different mechanism).

●       Plaque Psoriasis Medicines

●       Psoriatic Arthritis Treatments

●       IL-17 Inhibitors

FAQs

Q1.

What is ixekizumab used for?

It's used to treat moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.

Q2.

How is ixekizumab given?

As a subcutaneous injection, typically self-administered after training, following a specific starting schedule that varies by condition, then continuing every 4 weeks.

Q3.

Does ixekizumab increase infection risk?

Yes, like other immune-targeted biologics, it can increase susceptibility to infections, which is why screening (including for tuberculosis) is done before starting and monitoring continues throughout treatment.

Q4.

Can ixekizumab be used in children?

Yes, for moderate-to-severe plaque psoriasis in children 6 years and older; other indications are approved for adults only.

Q5.

What is the link between ixekizumab and inflammatory bowel disease?

Rare cases of new-onset or worsening Crohn's disease or ulcerative colitis have been reported with ixekizumab, so new or worsening gastrointestinal symptoms should be reported to the treating doctor.

Disclaimer

The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.

;

Why MrMed?

Directly from

Directly from
Manufacturers

Quick Air

Quick Air
Delivery

Genuine

Genuine
Medicines

Up-to 85%

Up-to 85%
Discount

Why MrMed?

  • Genuine Medicines — Sourced from licensed manufacturers and their authorised distributors, with quality checks at every step.

  • Cold Chain Delivery — Temperature-controlled shipping for medicines that need it, to 4,000+ towns and cities across India.

  • Hard-to-Find Medicines — If a medicine is not available in India, we help you source it and support the documentation and approvals required.

  • Up to 85% Savings — Speciality treatments at a fraction of MRP.

We Create a Way. For You.

Serving customers and shipping medicines only within India.

Living with a serious health condition comes with enough challenges. Finding the right medicine shouldn't be one of them.

MrMed helps patients and caregivers in India buy speciality medicines online for cancer, kidney disease, heart conditions, and other complex long-term illnesses. If a prescribed medicine isn't available in India, we also help source and import it from trusted global suppliers while managing the required documentation and approvals.

From genuine medicine sourcing and cold chain delivery to patient support services, we make it easier to access treatment with confidence. Every step is built around one goal: helping you get the medicines you need, when you need them.

Why Patients Trust MrMed

  • 7,000+ speciality medicines across multiple therapeutic areas like oncology, nephrology, cardiology, and critical care medicines

  • Delivery to 4,000+ towns and cities across India

  • Up to 85% savings on speciality medicines

  • Medicines sourced from licensed manufacturers and authorised suppliers

  • Secure ordering through the MrMed website and app

  • Dedicated support for patients and caregivers

MrMed by the Numbers

The trust placed in MrMed is reflected in the lives we've been able to support.

  • ₹125+ crores saved by our users

  • ₹75 saved every second on cancer medicine, heart conditions, and more

  • Helping patients access treatment across India

Beyond Medicine Delivery

We support patients throughout their treatment journey with services that go beyond medicine delivery.

  • Guidance on Patient Assistance Programs (PAPs)

  • Support for accessing prescribed imported medicines

  • Dedicated customer support before and after your order

  • Assistance in finding difficult-to-access speciality medicines

Recognised for Excellence

MrMed has been recognised by leading industry platforms for our work in improving access to speciality healthcare through trust, innovation, and responsible care.

  • Healthcare Start-up of the Year by the Federation of Indian Chambers of Commerce & Industry (FICCI)

  • ET Pharma Game Changer Award for our contribution to speciality healthcare access

  • Selected for the Google Play Accelerator India 2026 Cohort, joining 20 AI-first startups chosen by Google

  • BW Healthcare 40 Under 40 recognition received by our founders, Dev and Saurab, in different years

  • Recognised among Brands to Watch Out For by Local Samosa

Trusted Healthcare, Verified Standards

MrMed is LegitScript Certified, reflecting our commitment to trusted, transparent, and responsible healthcare services. This certification reinforces our focus on maintaining high standards in online healthcare practices and patient safety.

Start Your Treatment Journey with Confidence

Whether you're ordering a regular prescription or looking for a difficult-to-find speciality medicine, MrMed is here to help.

Explore our catalogue and order medicines online with confidence through the MrMed website or app.

Download the MrMed App For Super-Fast Delivery!

MrMed is India's largest online pharmacy for super speciality medicines, offering an extensive range of drugs that cater to diverse health needs across the country.

MrMed

Genuine medicines delivered all over India

MrMed

Sourced directly from reputable manufacturers

MrMed

Efficient storage for temperature-sensitive medicines

MrMedMrMed

Available on Google Play & App Store